Precigen's PAPZIMEOS Achieves Long-Term Success in Treating Recurrent Respiratory Papillomatosis

Pioneering Treatment for Recurrent Respiratory Papillomatosis Achieves Long-Term Success

Precigen, Inc., a biopharmaceutical firm dedicated to advanced precision medicine, showcases significant advancements in the treatment of recurrent respiratory papillomatosis (RRP) with its therapy PAPZIMEOS™ (zopapogene imadenovec-drba). Recent long-term follow-up data, presented at the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) 2025 Annual Meeting, highlights the effectiveness of the therapy, particularly in maintaining treatment response over an extended period. The study reveals that 83% of the 18 complete responders sustain their status after a median follow-up of 36 months, presenting a compelling case for PAPZIMEOS as a long-term solution for patients battling RRP.

The pivotal study indicates that 51% of participants achieved a complete response within the first year of treatment. This achievement is particularly noteworthy as it correlates with a dramatic decrease in the need for surgical interventions: 86% reduction in Year 1, 91% in Year 2, and an impressive 95% in Year 3 when compared to the year before patients began treatment. This reduction not only underscores the therapy's effectiveness but also emphasizes its potential to significantly enhance the quality of life for individuals afflicted by RRP, who often endure repetitive surgeries to manage their condition. Dr. Helen Sabzevari, President and CEO of Precigen, articulates the therapy's impact on patient lives, indicating that it provides freedom from frequent surgical procedures, ultimately improving overall well-being.

In addition to its efficacy, the safety profile of PAPZIMEOS is robust, with no new safety events reported during the follow-up period. The absence of dose-limiting toxicities or serious adverse events greater than Grade 2 further cements the therapy’s position as a safe treatment option. The full approval granted by the FDA in August 2025 marks a significant milestone, as PAPZIMEOS becomes the first and only approved therapy specifically for adults with RRP. This groundbreaking achievement not only represents a technological leap in treating RRP but also redefines the standard of care for patients, instilling confidence in healthcare providers regarding the treatment's reliability.

In conclusion, the developments surrounding PAPZIMEOS underscore Precigen's commitment to innovating patient-centric solutions in the biopharmaceutical landscape. The promising long-term data positions PAPZIMEOS as a transformative force in the treatment of RRP, potentially reshaping therapeutic approaches and enhancing patient outcomes across the board. As the biopharmaceutical industry continues to evolve, Precigen's advancements signal hope for those suffering from chronic conditions, paving the way for improved treatment modalities and better quality of life.

Moreover, these results bolster Precigen's reputation as a leader in precision medicine, illustrating its potential to address complex diseases with innovative therapies. As the company continues to develop and refine its offerings, it reinforces the importance of patient-centric approaches in the evolving healthcare landscape.